JP2022547541A5 - - Google Patents

Info

Publication number
JP2022547541A5
JP2022547541A5 JP2022515692A JP2022515692A JP2022547541A5 JP 2022547541 A5 JP2022547541 A5 JP 2022547541A5 JP 2022515692 A JP2022515692 A JP 2022515692A JP 2022515692 A JP2022515692 A JP 2022515692A JP 2022547541 A5 JP2022547541 A5 JP 2022547541A5
Authority
JP
Japan
Prior art keywords
sequence
eye
raav particles
unit dose
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022515692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547541A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/062066 external-priority patent/WO2021050094A1/en
Application filed filed Critical
Priority claimed from PCT/US2020/050079 external-priority patent/WO2021050649A1/en
Publication of JP2022547541A publication Critical patent/JP2022547541A/ja
Publication of JP2022547541A5 publication Critical patent/JP2022547541A5/ja
Priority to JP2025077233A priority Critical patent/JP2025118798A/ja
Withdrawn legal-status Critical Current

Links

JP2022515692A 2019-09-11 2020-09-10 アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法 Withdrawn JP2022547541A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025077233A JP2025118798A (ja) 2019-09-11 2025-05-07 アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962899070P 2019-09-11 2019-09-11
US62/899,070 2019-09-11
US201962913648P 2019-10-10 2019-10-10
US62/913,648 2019-10-10
PCT/US2019/062066 WO2021050094A1 (en) 2019-09-11 2019-11-18 Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
USPCT/US2019/062066 2019-11-18
US202062959784P 2020-01-10 2020-01-10
US62/959,784 2020-01-10
US202062971835P 2020-02-07 2020-02-07
US62/971,835 2020-02-07
US202063019190P 2020-05-01 2020-05-01
US63/019,190 2020-05-01
US202063030819P 2020-05-27 2020-05-27
US63/030,819 2020-05-27
US202063063203P 2020-08-07 2020-08-07
US63/063,203 2020-08-07
PCT/US2020/050079 WO2021050649A1 (en) 2019-09-11 2020-09-10 Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025077233A Division JP2025118798A (ja) 2019-09-11 2025-05-07 アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法

Publications (2)

Publication Number Publication Date
JP2022547541A JP2022547541A (ja) 2022-11-14
JP2022547541A5 true JP2022547541A5 (enExample) 2023-08-24

Family

ID=75273816

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022515692A Withdrawn JP2022547541A (ja) 2019-09-11 2020-09-10 アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法
JP2025077233A Pending JP2025118798A (ja) 2019-09-11 2025-05-07 アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025077233A Pending JP2025118798A (ja) 2019-09-11 2025-05-07 アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法

Country Status (16)

Country Link
US (1) US20210100856A1 (enExample)
EP (2) EP4696318A1 (enExample)
JP (2) JP2022547541A (enExample)
DK (1) DK4027983T3 (enExample)
ES (1) ES3063491T3 (enExample)
FI (1) FI4027983T3 (enExample)
HR (1) HRP20260137T1 (enExample)
LT (1) LT4027983T (enExample)
MX (1) MX2022002961A (enExample)
PL (1) PL4027983T3 (enExample)
PT (1) PT4027983T (enExample)
RS (1) RS67774B1 (enExample)
SI (1) SI4027983T1 (enExample)
SM (1) SMT202600070T1 (enExample)
TW (1) TW202117016A (enExample)
UY (1) UY38881A (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025010334A2 (en) * 2023-07-05 2025-01-09 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
AR130449A1 (es) 2023-09-11 2024-12-11 Cuarsagro Sa Conjunto de montaje y extracción de olores para inodoros
WO2026019797A1 (en) * 2024-07-16 2026-01-22 4D Molecular Therapeutics, Inc. Methods for treating wet age-related macular degeneration with adeno-associated virus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544136B2 (ja) * 1986-05-23 1996-10-16 第一製薬株式会社 硫酸化多糖体ds4152を含有する血管新生抑制剤及び抗腫瘍剤
TW201105363A (en) * 2009-07-14 2011-02-16 Univ Yamagata Eye drop for macular edema treatment
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
US20160051526A1 (en) * 2013-04-09 2016-02-25 Cresset Biomolecular Discovery Ltd The Local Treatment of Inflammatory Ophthalmic Disorders
CN117531025A (zh) * 2016-06-16 2024-02-09 阿德夫拉姆生物技术股份有限公司 使用aav2变体和阿柏西普治疗amd
KR102616820B1 (ko) * 2017-03-17 2023-12-21 애드베룸 바이오테크놀로지스, 인코포레이티드 향상된 유전자 발현을 위한 조성물 및 방법
KR20210068014A (ko) * 2018-08-20 2021-06-08 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP2024515459A5 (enExample)
JP2025506383A5 (enExample)
JP2025506681A5 (enExample)
JP2021503914A5 (enExample)
FI4027983T3 (fi) Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla
JP2022141856A (ja) 滲出型加齢性黄斑変性の治療のための組成物
JP2022522776A5 (enExample)
US20200297869A1 (en) Sequential intravitreal administration of aav gene therapy to contralateral eyes
RU2018142768A (ru) Варианты капсидов аденоассоциированного вируса и способы их применения
JP2020537637A5 (enExample)
JP2020526514A5 (enExample)
JP2015523060A5 (enExample)
CN114375195A (zh) 使用编码阿柏西普的aav2变体治疗眼新血管疾病的方法
US20250137011A1 (en) Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
JP2021511030A5 (enExample)
JP2022545967A5 (enExample)
JP2024148177A (ja) アフリベルセプトをコードするaav2バリアントを使用する眼内血管新生疾患を処置する方法
JP2025509568A5 (enExample)
JP2023545229A5 (enExample)
WO2023158990A1 (en) Method of reducing cst fluctuation in neovascular amd by a recombinant adeno-associated virus
US20230175015A1 (en) Immunosuppressive agents and viral delivery re-dosing methods for gene therapy
JP2022533983A5 (enExample)
JP2022523050A5 (enExample)
JP2023531289A (ja) 眼病態の処置のためのdna構造
JP2022518354A5 (enExample)